Overall Survival in the Intervention Arm of a Randomized Controlled Screening Trial for Prostate Cancer Compared with a Clinically Diagnosed Cohort

European Urology

Volumn 53, Issue 1, 2008, Pages 91-98

  Vis, André N ^a   Roemeling, Stijn ^a   Reedijk, Ardine M J ^b   Otto, Suzie J ^a   Schröder, Fritz H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Integraal Kankercentrum Rotterdam   (Netherlands)

Author keywords

Prognosis; Prostate; Screening; Survival; Treatment

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CLINICAL EXAMINATION; CLINICAL TRIAL; COHORT ANALYSIS; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; WATCHFUL WAITING;

AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; FOLLOW-UP STUDIES; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NETHERLANDS; POPULATION SURVEILLANCE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 36448963769     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.06.001     Document Type: Article

References (38)

1. Beemsterboer P.M., de Koning H.J., Birnie E., et al. Advanced prostate cancer: course, outcome and cost implications. Prostate 40 (1999) 97-104
2. Chu K.C., Tarone R.E., and Freeman H.P. Trends in prostate cancer mortality among black men and white men in the United States. Cancer 97 (2003) 1507-1516
3. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
4. Baade P.D., Coory M.D., and Aitken J.F. International trends in prostate-cancer mortality: the decrease in continuing and spreading. Cancer Causes Control 15 (2004) 237-241
5. Oliver S.E., Gunnell D., and Donovan J.L. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 355 (2000) 1788-1789
6. Oliver S.E., May M.T., and Gunnell D. International trends in prostate-cancer mortality in the 'PSA-era'. Int J Cancer 92 (2001) 893-898
7. Tuljapurkar S., Li N., and Boe C. A universal pattern of mortality decline in the G7 countries. Nature 405 (2000) 789-792
8. Gann P.H. Interpreting recent trends in prostate cancer incidence and mortality [editorial]. Epidemiology 8 (1997) 117-120
9. Bartsch G., Horninger W., Klocker H., et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the federal state of Tyrol, Austria. Urology 58 (2001) 417-424
10. Marcus P.M., Bergstrahl E.J., Fagerstrom R.M., et al. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst 92 (2000) 1308-1316
11. Feuer E.J., Merrill R.M., and Hankey B.F. Cancer surveillance series: interpreting trends in prostate cancer-part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 91 (1999) 1025-1032
12. Chu K.C., Miller B.A., Feuer E.J., et al. A method for partitioning cancer mortality trends by factors associated with diagnosis: an application to female breast cancer. J Clin Epidemiol 47 (1994) 1451-1461
13. Roobol MJ, Schröder FH, editor. The European Randomized Study of Screening for Prostate Cancer (ERSPC): rational, structure, and preliminary results 1994-2003. BJU Int 2004;92(Suppl):111-7.
14. Schröder F.H., van der Maas P., Beemsterboer P., et al. Evaluation of rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study on Screening for Prostate Cancer. J Natl Cancer Inst 90 (1998) 1817-1823
15. Van der Cruijsen-Koeter I.W., van der Kwast T.H., Schröder F.H., et al. Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-section Rotterdam. J Natl Cancer Inst 95 (2003) 1462-1466
16. Mostofi F.K. Grading of prostatic adenocarcinoma. Cancer Chemother Rep 59 (1975) 111-117
17. Black W.C., Haggstrom D.A., and Welch H.G. All-cause mortality in randomized trials of cancer. J Natl Cancer Inst 94 (2002) 167-173
18. Stata statistical software: release 9.0. College Station (TX): Stata Corporation; 2005.
19. Voutilainen E.T., Dickman P.W., and Hakulinen T. SURV2: relative survival analysis program, version 2.02a (1998), Finnish Cancer Registry, Helsinki
20. Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics 38 (1982) 933-942
21. Roemeling S., Roobol M., Otto S.Z., et al. Feasibility study of adjustment of contamination and non-compliance in a prostate cancer screening trial. Prostate 67 (2007) 1053-1060
22. Draisma G., Boer R., Otto S., et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95 (2003) 868-878
23. Steyerberg E.W., Roobol M.J., Kattan M.W., et al. Prediction of indolent prostate cancer: Validation and updating of a prognostic nomogram. J Urol 177 (2007) 107-112
24. Dutch Comprehensive Cancer Center. Available at URL: http://www.ikcnet.nl.
25. US National Cancer Center. Available at URL: http://www.cancer.gov.
26. Ries LAG, Eisner MP, Kosary CL, et al, editors. SEER Cancer Statistics Review, 1975-2002, National Cancer Institute. Available at URL: http://seer.cancer.gov/csr/1975_2002.
27. Johannson J.E., Andrén O., Andersson S.O., et al. Natural history of early, localized prostate cancer. JAMA 291 (2004) 2713-2719
28. Albertsen P.C., Hanley J.A., and Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 (2005) 2095-2101
29. Feuer E.J., Mariotto A., Merrill R., et al. Modelling the impact of the decline in distant stage disease on prostate carcinoma incidence rates. Cancer 95 (2002) 870-880
30. Parker C., Muston D., Melia, et al. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall-survival. Br J Cancer 94 (2006) 1361-1368
31. Bill-Axelson A., Holmberg L., Ruutu M., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. New Engl J Med 352 (2005) 1977-1984
32. Peeters S.T., Heemsbergen W.D., Koper P.C., et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2005) 1990-1996
33. McLeod D.G., Iversen P., See W.A., et al. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 97 (2006) 247-254
34. Cooperberg M.R., Grossfeld G.D., and Lubeck D.P. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 95 (2003) 981-989
35. Feinleib M., and Zelen M. Some pitfalls in the evaluation of screening programs. Arch Environ Health 9 (1969) 412-415
36. Gann P.H., Hennekens C.H., Stampfer M.J., et al. A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer. JAMA 273 (1995) 289-294
37. Otto S.J., Schröder F.H., and de Koning H.J. Low all-cause mortality in the volunteer-based Rotterdam section of the European randomised study of screening for prostate cancer: self-selection bias?. J Med Screen 11 (2004) 89-92
38. Schröder F.H. The motion: there is evidence that prostate cancer screening does more good than harm. Eur Urol 50 (2006) 377-379